Replies to post #33715 on Relief Therapeutics Holding AG (RLFTF)

[JulieA]

Thanks for posting. So with that article, seems like we should be hearing something around January 28th? Thoughts? It’s so hard to wait ;)

[mc67]

Javitt notes that in their trial enrolled the last patient on December 24, 2020, and they “expect to have the last patient out from the study on January 21, with topline data to follow shortly thereafter.”

The trial’s Data Safety Monitoring Board has reviewed the trial data twice and both times declared it safe to continue. Javitt says, “We expect topline data at the end of the month and that may well trigger regulatory action if we have a positive readout.”

[dmsrz8]

“Javitt notes that in their trial enrolled the last patient on December 24, 2020, and they “expect to have the last patient out from the study on January 21, with topline data to follow shortly thereafter.”

[dmsrz8]

“While the drug is being studied, it has been granted use of Expanded Access Programs (EAPs), also known as Compassionate Use. Of 319 companies developing COVID-19 treatments, only 20 have created EAPs to treat the sickest patients, and NeuroRx is one of them.”

[dmsrz8]

“A clinical trial is expected to start this month at Cantonal Hospital, Baselland (Switzerland) with an inhaled formulation to prevent COVID-19-related ARDS. They are also in talks with the Department of Health and Human Services and BARDA to supply the drug for studies of inhaled aviptadil compared to other drugs in COVID-19.”